Lichen Planus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Lichen Planus Market Outlook

Thelansis’s “Lichen Planus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lichen Planus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Lichen Planus Overview

Lichen planus is a chronic autoimmune disease impacting the skin, oral and genital mucosa, scalp, and nails. Its lesions are characterized by six features known as the six P's: flat-topped, purple, polygonal, pruritic, papules, and plaques. These papules and plaques, which are itchy and violet in color, are typically found on the wrists, lower back, and ankles. Wickham striae, a lattice-like network of white lines, can be observed, especially on the buccal mucosa, which may also exhibit erosions. Drug-induced lichen planus, or lichenoid drug eruption, often presents similarly and is mainly distributed due to photosensitivity, making it hard to distinguish from the idiopathic form. The exact cause of lichen planus is unknown. However, it is believed to be a T-cell-mediated autoimmune disease triggered by various external factors such as viruses, drugs, or allergens. These factors lead to changes in self-antigens on the skin and activation of cytotoxic CD8+ T cells, causing T-cell targeting and apoptosis of basal keratinocytes. Several conditions, including lupus erythematosus (LE), lichen nitidus, psoriasis, secondary syphilis, pityriasis rosea, erythema dyschromicum perstans, graft versus host disease, and keratosis lichenoides chronica, may mimic lichen planus. Differentiating between LP and LE can be challenging, especially when they affect the scalp or mouth. A biopsy with direct immunofluorescence (DIF) is valuable in such cases. Co-occurrence of both diseases has been reported and may be linked to antimalarial treatments for LE. Cutaneous lichen planus often resolves on its own within one to two years, but hyperpigmentation can persist. Oral lichen planus may clear spontaneously within five years but frequently has a chronic, recurring nature. Hair loss from lichen planopilaris is permanent. Withdrawal of the causative medication is the primary treatment for drug-induced lichen planus. Topical corticosteroids are the initial treatment for mucosal erosive lichen planus, while systemic corticosteroids are an option for severe, widespread cases affecting the mouth, skin, or genitals. Dermatologist referral for systemic therapy with expensive and potentially toxic oral retinoids or immunosuppressants may be necessary for severe, treatment-resistant lichen planus. Oral involvement occurs in approximately 50% of cases and may occur independently of skin lesions. Vulvar and vaginal mucosae are frequently affected, and undiagnosed vulvar lichen planus is common in women with oral mucosal symptoms. Genital involvement, particularly of the glans penis, is frequent in men, and nail involvement is seen in up to 10% of cases. The average age at diagnosis is 62.4 years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: